Clinical trials: Major Depressive Disorder, Healthy Volunteer
Mood Disorders, Healthy
Cholinergic Modulation of Condition and Emotion in Mood Disorders: Functional Neuroimaging Studies
This study looks at the role of a specific brain chemical system in the mood and attention symptoms seen in major depression and bipolar disorders using functional brain imaging.
- Conditions
- Mood Disorders, Healthy, Unipolar Depression, Bipolar Depression
- Trial name
- NCT00055575
- Testing
- Scopolamine Nasal Spray
- Where
- United States
- Volunteers
- 197 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Major Depressive Disorder
SPL026 (DMT Fumarate) in Healthy Subjects and MDD Patients
SPL026 (N,N-dimethyltryptamine [DMT] fumarate) is a psychedelic tryptamine being developed as a therapy for patients with major depressive disorder (MDD).
- Trial name
- NCT04673383
- Testing
- SPL026
- Where
- 2 sites in United Kingdom
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Small Pharma Ltd
Healthy Volunteers, Depression
Neurobiology of Suicide
Background: There are no good treatments for people considering suicide. Researchers want to study suicide with questions, blood tests, brain imaging, and sleep studies.
- Trial name
- NCT02543983
- Testing
- Magnetic Resonance Imaging scanner, 3T, NeurOptics PLRTM-3000 Pupillometer, Experimental Anxiety Devices
- Where
- United States
- Volunteers
- 325 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Major Depressive Disorder, Healthy Volunteer
First-In-Human (FIH), Single Ascending Dose (SAD) Study and Multiple Ascending Dose (MAD) Study of SP-101 Injection
The goal of this First-In-Human (FIH) trial is to learn about safety, tolerability and pharmacokinetics of single and multiple ascending doses of SP-101 in healthy adult volunteers.
- Trial name
- NCT07334249
- Testing
- SP-101 injection
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Synphatec (Shanghai) Biopharmaceutical Technology Co., Ltd.
Major Depressive Disorder
Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine
A 6-cohort single ascending dose (SAD) study will be conducted in healthy volunteers utilizing a slow-infusion intravenous (IV) route of administration.
- Trial name
- NCT04711005
- Testing
- (2R,6R)-Hydroxynorketamine hydrochloride
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Major Depressive Disorder
Pharmacokinetics and Safety of Desvenlafaxine in Korean Healthy Subjects Following Single and Multiple Oral Doses of Desvenlafaxine Succinate Sustained Release Tablet
To evaluate the pharmacokinetics and safety of single dose and multiple doses of desvenlafaxine in Korean healthy subjects and compare to westerners.
- Trial name
- NCT01443208
- Testing
- desvenlafaxine
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Pfizer
Major Depressive Disorder
A Relative Bioavailability Food Effect Study of LY03005
The objective if this study is to assess the relative bio-availability of single oral doses of 80 mg LY03005 tablets administered to healthy subjects under fed versus fasted conditions in a 2-period, crossover trial.
- Trial name
- NCT03822065
- Testing
- LY03005
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Healthy Volunteer, Major Depressive Disorder
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
Background: Most medications that treat depression take weeks or months to work. Researchers want to develop fast-acting treatments. One dose of ketamine has a rapid antidepressant effect.
- Conditions
- Healthy Volunteer, Major Depressive Disorder, Depression
- Trial name
- NCT03065335
- Testing
- Ketamine, Cobot TS MV robotic arm for TMS, NeurOptics PLRTM-30000 Pupillometer
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
OCD, Major Depressive Disorder (MDD)
Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics
This is an observational study which does NOT directly administer a psychedelic substance but rather recruits participants who are already participating in another clinical trial in which they may receive a serotonergic…
- Conditions
- OCD, Major Depressive Disorder (MDD), Alcohol Use Disorder (AUD), Healthy Volunteer
- Trial name
- NCT06624137
- Testing
- Serotonergic Psychedelic
- Where
- 2 sites in United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Yale University
Major Depressive Disorder
Oral Tyramine Pressor Response Study of CX157 Tablets in Healthy Male Volunteers
The objectives of this study were to examine the cardiovascular sensitivity to oral tyramine after establishment of steady state with CX157 Modified Release (MR) Tablets, 125 mg administered twice per day (BID) in healthy…
- Trial name
- CX157-112 (NCT01633437)
- Testing
- CX157
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- CeNeRx BioPharma Inc.
Depression, Healthy
Bone Loss in Premenopausal Women With Depression
The purpose of this study is to determine whether women with major depression lose bone mass at a faster rate than women without depression.
- Conditions
- Depression, Healthy, Osteopenia, Osteoporosis
- Trial name
- NCT00006180
- Testing
- Alendronate
- Where
- United States
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Major Depression, Unipolar Depression
Imaging Serotonin 5HT1A Receptors in Patients With Major Depressive Disorder
Background: Medications to treat major depression act on a brain chemical called serotonin, which binds to receptors on brain cells.
- Conditions
- Major Depression, Unipolar Depression, Depression, Anxiety Disorder
- Trial name
- NCT01313403
- Testing
- Antidepressant (SSRI)
- Sponsor
- National Institute of Mental Health (NIMH)
Major Depressive Disorder
Evaluation of the Effects of Duloxetine on Norepinephrine
The purpose of this study is to evaluate how taking duloxetine 60mg every day affects the transfer of two normal body chemicals, 3,4-dihydroxyphenylglycol (DHPG) and norepinephrine (NE), across cells in blood and cerebrospinal…
- Trial name
- NCT00414323
- Testing
- Duloxetine, Escitalopram
- Where
- 2 sites in United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
Evaluation of the Safety and Pharmacokinetics of MSI-195 to a Commercial S-Adenosylmethionine
This study was a pharmacokinetic and safety evaluation of the S-adenosylmethionine formulation MSI-195, and a commercial comparator. The study was broken into two stages.
- Trial name
- NCT04623034
- Testing
- Ademetionine
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- MSI Methylation Sciences, Inc.
Suicidal Ideation, Major Depressive Disorder
The Effect of Ketamine on Mechanises Underlying Suicidal Ideation and Drug-resistant Major Depression
Suicide attempts are a serious concern worldwide. Currently, existing drugs take about three weeks to show effect on suicidal thoughts and drives.
- Conditions
- Suicidal Ideation, Major Depressive Disorder, Healthy Participants
- Trial name
- NCT02037503
- Testing
- Ketamine, Saline
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Healthy Volunteers (Part 1), Major Depressive Disorder (Part 2)
Pharmacokinetics - Pharmacodynamic Study of HT-2157 in Healthy Subjects and in Patients With Major Depressive Disorder
This is a two part study. The objective of Part 1 is to evaluate the safety, tolerability, and pharmacokinetics of HT-2157 in healthy normal volunteers Part 2 is a randomized, double-blind, placebo-controlled, multiple (21-day)…
- Trial name
- NCT01413932
- Testing
- HT-2157
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Dart NeuroScience, LLC
Major Depressive Disorder
An Open-label, Adaptive Design, Positron Emission Tomography Study in Healthy Male Participants to Characterize Receptor Occupancy by MIJ821 in the Brain
The purpose of this study is to confirm binding of MIJ821 to the NR2B-containing NMDA receptors in the human brain and assess the PC-RO relationship over time using positron emission tomography (PET).
- Trial name
- NCT05666687
- Testing
- MIJ821
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Major Depressive Disorder, Obsessive-Compulsive Disorder
Bioequivalence Study of Paroxetine Tablets and Paxil® Under Fasting and Fed Conditions in Chinese Healthy Volunteers
The objective of this study is to compare the rate and extent of absorption of paroxetine hydrochloride 20 mg tablets (test) and Paxil® (reference) administered as 20 mg tablet under fed conditions.
- Conditions
- Major Depressive Disorder, Obsessive-Compulsive Disorder, Panic Disorder, Social Anxiety Disorder
- Trial name
- NCT03504475
- Testing
- Paroxetine Hydrochloride Tablet 20 mg, Paxil® 20 mg
- Where
- 2 sites in China
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Beijing Tongren Hospital
Depressive Disorder, Major
A Study to Evaluate the Effect of Genotype on LY2216684
The study will evaluate how genetic profiles respond to LY2216684 and the effect of Quinidine on the pharmacokinetics (PK) of LY2216684 in a specific genetic profile. Side effects will be documented.
- Trial name
- NCT01460381
- Testing
- LY2216684, Quinidine
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
A Study to Measure if There is Any Difference in How the Body Breaks Down or Inactivates Either Fluoxetine or LY2216684 When Both of These Medicines Are Given Together.
The purpose of this study is to measure if there is any difference in how the body breaks down or inactivates either fluoxetine or LY2216684 when both of these medicines are given together.
- Trial name
- NCT01243957
- Testing
- LY2216684, Fluoxetine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company